Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pulmatrix Inc PULM

Healthcare Biotechnology
Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious... see more

Recent & Breaking News (NDAQ:PULM)

20 Biggest Mid-Day Losers For Friday

Benzinga.com  November 4, 2016

Pulmatrix Reports Third Quarter 2016 Financial Results and Business Update

PR Newswire November 4, 2016

Pulmatrix Will Present Promising New Data at the North American Cystic Fibrosis Conference on October 27-29, 2016

PR Newswire October 11, 2016

Pulmatrix Highlights Recent Report Predicting Rapid Growth for Inhaled Drug Delivery Methods

PR Newswire September 23, 2016

Stocks Hitting 52-Week Lows

Benzinga.com  August 30, 2016

Pulmatrix Receives Orphan Drug Designation from the FDA for Inhaled Drug to Treat Pulmonary Fungal Infections in Cystic Fibrosis Patients

PR Newswire August 17, 2016

Breathing Easier: Pharma Successfully Leveraging Smoother EU Regulatory Specs

Canada NewsWire August 11, 2016

10 Biggest Mid-Day Losers For Wednesday

Benzinga.com  July 20, 2016

10 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  July 19, 2016

Pulmatrix's New Life Sciences Animation Spotlights Inhaled Drug Delivery to Lungs

PR Newswire June 27, 2016

Pulmatrix Added to Russell Microcap Index

PR Newswire June 24, 2016

Pulmatrix Named "Stock of the Year 2016" by Konlin Letter

PR Newswire June 21, 2016

Pulmatrix's CEO Eyes $25 Billion COPD Market for Its Inhaled Drug Delivery Technology

ACCESS Newswire June 7, 2016

Pulmatrix Completes Dosing in Pilot Pharmacokinetic Evaluation of PUR0200 in Healthy Normal Volunteers

PR Newswire May 25, 2016

Pulmatrix Reports Q1 2016 Financial Results

PR Newswire May 5, 2016

New Global Energy, Inc. Launches Moringa Reserve, LLC

PR Newswire May 5, 2016

Pulmatrix's iSPERSE 'Inhaled' Drug Delivery Technology Offers Hope to Patients with Pulmonary Lung Disease

PR Newswire March 23, 2016

Pulmatrix To Present at 2016 Cowen and Company 36th Annual Healthcare Conference

PR Newswire March 4, 2016

Capsugel, Pulmatrix Enter Partnership To Develop, Manufacture Novel Inhaled Therapeutics

Press Releases February 16, 2016

UPDATE: Fairchild Semi Reiterates Co. Entered Merger Deal with ON Semi for $20/Share in Cash

Press Releases February 16, 2016